Skip to main content
ET

ECM Therapeutics

ECM Therapeutics develops natural biomaterials that leverage the body's regenerative processes to promote healing in patients with tissue damage from injuries and diseases. Their technology enhances recovery outcomes by utilizing these biomaterials to stimulate tissue repair and regeneration.

Wa, United StatesFounded 20188300+ followers
Updated 4 months ago

Funding

$26.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Tissue damage resulting from injuries and diseases often leads to inflammation and impaired functionality, requiring effective regenerative medicine strategies. Current approaches may not fully leverage the body's natural healing mechanisms for optimal tissue repair and restoration.

Solution

ECM Therapeutics develops and manufactures therapeutic products derived from naturally occurring extracellular matrix (ECM) to address unmet medical needs in regenerative medicine. Their technology harnesses the inherent regenerative properties of ECM, a reservoir of potent signaling molecules found within tissues, to mitigate inflammation and promote functional tissue restoration following injury. By utilizing ECM-based materials, the company aims to influence cell behavior and create an ideal microenvironment for tissue reconstruction. This approach facilitates the body's natural ability to repair and regenerate damaged tissues, offering potential solutions for various clinical markets, including gastrointestinal, musculoskeletal, optic, and central nervous system applications.

Target Audience

The primary target audience includes medical professionals and patients seeking regenerative medicine solutions for tissue damage resulting from injuries and diseases.

Features

  • Utilizes naturally occurring extracellular matrix (ECM) as a source of signaling molecules.
  • Products aim to mitigate inflammation in damaged tissues.
  • Designed to promote the restoration of functional tissue following injury.
  • Targets various clinical markets including gastrointestinal, musculoskeletal, optic and central nervous system.
This profile is AI-generated and may contain inaccuracies.